Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company focused on the discovery and development of pharmaceutical products for diseases of the Central Nervous System (CNS) and pain. The company specializes in innovative therapies targeting unmet medical needs in neurology and pain management, with key programs including phase III trials of safinamide for Parkinson's disease patients and ralfinamide for neuropathic pain. Its research and development activities span Italy and the United States, emphasizing novel molecules to address complex neurological disorders. Operating in the biotechnology sector, Newron Pharmaceuticals SpA advances its pipeline through rigorous clinical testing to deliver potential new treatments. Founded in 1998 and headquartered in Bresso, Italy, the company plays a vital role in the healthcare industry by contributing to advancements in CNS therapeutics and pain relief solutions for patients worldwide.